Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
Foreign body response
Immune microenvironment
Long acting drug delivery
Subcutaneous implants
Tenofovir alafenamide
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
28
03
2023
revised:
19
04
2023
accepted:
23
04
2023
pmc-release:
01
06
2024
medline:
14
6
2023
pubmed:
30
4
2023
entrez:
29
4
2023
Statut:
ppublish
Résumé
Several implantable long-acting (LA) delivery systems have been developed for sustained subcutaneous administration of tenofovir alafenamide (TAF), a potent and effective nucleotide reverse transcriptase inhibitor used for HIV pre-exposure prophylaxis (PrEP). LA platforms aim to address the lack of adherence to oral regimens, which has impaired PrEP efficacy. Despite extensive investigations in this field, tissue response to sustained subcutaneous TAF delivery remains to be elucidated as contrasting preclinical results have been reported in the literature. To this end, here we studied the local foreign body response (FBR) to sustained subdermal delivery of three forms of TAF, namely TAF free base (TAF
Identifiants
pubmed: 37120032
pii: S0168-3659(23)00287-0
doi: 10.1016/j.jconrel.2023.04.037
pmc: PMC10330370
mid: NIHMS1897615
pii:
doi:
Substances chimiques
Tenofovir
99YXE507IL
Anti-HIV Agents
0
Adenine
JAC85A2161
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
116-127Subventions
Organisme : NIAID NIH HHS
ID : R01 AI120749
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM127558
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Références
J Invest Dermatol. 1992 Apr;98(4):459-62
pubmed: 1548429
J Control Release. 2018 Sep 28;286:315-325
pubmed: 30092254
Biomed Microdevices. 2019 May 18;21(2):47
pubmed: 31104136
BMJ Open. 2022 Jan 06;12(1):e052880
pubmed: 34992111
J Pharm Biomed Anal. 2011 Sep 10;56(2):390-401
pubmed: 21715120
Int J Pharm. 2020 Sep 25;587:119623
pubmed: 32663582
Sci Transl Med. 2012 Sep 12;4(151):151ra125
pubmed: 22972843
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31871073
Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):492-506
pubmed: 32768562
Pharmaceutics. 2019 Jul 04;11(7):
pubmed: 31277461
J Invest Dermatol. 2021 Mar;141(3):496-502
pubmed: 32919759
Am J Primatol. 2014 Sep;76(9):801-27
pubmed: 24723482
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
Immunol Rev. 2015 Mar;264(1):60-73
pubmed: 25703552
Adv Ther (Weinh). 2021 Mar;4(3):
pubmed: 33997267
Cell Mol Life Sci. 2014 Jul;71(13):2443-50
pubmed: 24445815
Bioeng Transl Med. 2022 Mar 02;7(3):e10300
pubmed: 36176611
Adv Ther (Weinh). 2022 Feb;5(2):
pubmed: 35815229
Nat Rev Immunol. 2019 Aug;19(8):490-502
pubmed: 30992525
Antiviral Res. 2016 Jan;125:63-70
pubmed: 26640223
J Control Release. 2019 Jul 28;306:89-96
pubmed: 31136811
Nat Mater. 2017 Jun;16(6):671-680
pubmed: 28319612
J Infect Dis. 2019 Oct 22;220(11):1826-1833
pubmed: 31362305
Curr Opin HIV AIDS. 2018 Jul;13(4):374-380
pubmed: 29794816
Sci Transl Med. 2023 Jun 28;15(702):eadg2887
pubmed: 37379369
Skin Pharmacol Physiol. 2005 Mar-Apr;18(2):55-74
pubmed: 15767767
Nat Biomed Eng. 2023 Jan 19;:
pubmed: 36658344
Nat Rev Immunol. 2003 Jan;3(1):79-84
pubmed: 12511878
Immunol Today. 1992 Jul;13(7):250-4
pubmed: 1388651
N Engl J Med. 2012 Aug 2;367(5):399-410
pubmed: 22784037
Pharmaceutics. 2020 Oct 17;12(10):
pubmed: 33080776
Antioxid Redox Signal. 2011 Jan 15;14(2):261-73
pubmed: 20524846
J Diabetes Sci Technol. 2008 Sep;2(5):768-77
pubmed: 19885259
AIDS Res Hum Retroviruses. 2021 Jun;37(6):409-420
pubmed: 33913760
Nat Methods. 2017 Sep;14(9):873-876
pubmed: 28783155